Clinical Trials | A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with a specific type of advanced, recurrent (cancer that has returned after an initial response to treatment where it could no longer be detected), or metastatic (cancer that has spread from the primary site of origin into different areas of the body) solid tumor cancer with a SMARCA4 mutation for an oral SMARCA2 degrader (PRT7732, study drug) study. The purpose of this study is to test the safety of PRT7732 at different dose levels to find out what effects, good and/or bad, PRT7732 has on you and your type of cancer. This study is the first time that the study drug, PRT7732, has been given to humans. The information collected from you and other participants in this study will be used to decide the most appropriate dose of PRT7732 that should be used for studies that may be conducted in the future. In this study, you will have a Screening Visit to determine if you are eligible to receive PRT7732. If you are eligible to participate in the research, you will be enrolled in the study. Cycles will continue until your cancer progresses. Each Cycle is 21 days. Treatment visits may last anywhere from 2-8 hours. Many tests associated with the Screening Visit and the other study visits are performed as part of your usual cancer care. You may be familiar with these tests. If not, please ask the study staff to explain any tests you do not understand. If you are not eligible for this study, your study doctor will tell you why. You will be paid a total of $520 or $585 for completing the study. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future. For questions, contact: [email protected]